UnitedHealthcare (UHC) announced in the March issue of its Provider Network Bulletin that it will discontinue payment for consultation codes (CPT 99241–99255) later this year. Implementation of the policy will occur in two phases. On June 1, 2019, UHC will eliminate the consultation codes for practices with contracted rates based on a stated year 2010 or…
3 Tips to Optimize Practice Performance
Rheumatologists can build resilience through recovery and reframing, transforming stress so that it enhances performance…
GI Disease in Early Systemic Sclerosis Associated with Worse Outcomes
In patients with systemic sclerosis (SSc), gastrointestinal disease may be associated with lower quality of life and increased risk of death. Research showed that SSc patients with severe GI disease had markers of muscle inflammation, skin fibrosis and vasculopathy…
Duration & Treatment of Musculoskeletal Symptoms of Immunotherapy-Induced Arthritis
A new case series outlines the treatment and duration of symptoms of 10 patients experiencing the musculoskeletal manifestations of immune-related adverse events. Researchers found these symptoms may last for more than a year, but can generally be treated with low to moderate doses of corticosteroids…
History of Depression Is a Risk Factor for SLE in Women
Results from a 20-year, cohort study add to the evidence that depression increases the risk of developing an autoimmune disease, specifically SLE in women. Lead investigator Andrea Roberts, PhD, says, “There may be direct biological effects of depression that increase the risk of autoimmune disease.”…
Ankylosing Spondylitis Patients May Have Worse Oral Health
Patients with ankylosing spondylitis (AS) may have worse overall oral health than the general population. A recent study revealed an association between AS and oral ulcers…
Upadacitinib at the FDA
Upadacitinib is an investigational, oral, small molecule JAK1-selective inhibitor, which recently completed phase 3 clinical trials for treating patients with moderate to severe rheumatoid arthritis (RA). In late 2018, AbbVie Inc. submitted a New Drug Application to the U.S. Food and Drug Administration, as well as a marketing authorization application to the European Medicines Agency,…
U.S. House Democrats Introduce Sweeping Medicare for All Bill
WASHINGTON (Reuters)—Democrats in the U.S. House of Representatives unveiled an ambitious proposal to move all Americans into the government’s Medicare health insurance program, tapping into public frustration over the rising cost of healthcare that has become a key issue for the party as it seeks to gain control of Congress and the White House in…
U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant
WASHINGTON/NEW YORK (Reuters)—U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines. Executives from Abbvie Inc., AstraZeneca PLC., Sanofi SA, Pfizer…
Mortality Trends in Lupus Nephritis
According to results of a recent study of all-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014, the all-cause premature mortality rate improved among white, African American and Hispanic patients, with reduced risk of death from CVD and infection. Jorge et al. observed a 32% reduction in mortality. This improved survival may be explained by a combination of improvements in the management of ESRD and of underlying SLE…
- « Previous Page
- 1
- …
- 278
- 279
- 280
- 281
- 282
- …
- 814
- Next Page »